The new WHO global strategic initiative encouraged countries to adopt digital health tools to support universal health coverage.

In patients with plaque psoriasis, family history and palmoplantar involvement were among the predictors of early super response to bimekizumab.

Black and Hispanic patients with MCC are more likely to have tumors on UV-protected sites, which is associated with better outcomes.

Concomitant IBD reduces disease control and treatment response among patients with PsA receiving biologic therapy.

Ixekizumab was more effective for the treatment of mild to moderate psoriasis vs severe psoriasis at most time points through 52 weeks.

At 48 weeks of baricitinib, most patients (63.2%) achieved significant improvement in the severity of alopecia areata, with decreases seen among various trichoscopic signs from baseline. A real-world ...